Brasil
| Artigo
Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
Fecha
2017Registro en:
Frontiers In Immunology. Lausanne, v. 8, p. -, 2017.
1664-3224
WOS000403113800002.pdf
10.3389/fimmu.2017.00685
WOS:000403113800002
Autor
Aghamohammadi, Asghar
Abolhassani, Hassan
Kutukculer, Necil
Wassilak, Steve G.
Pallansch, Mark A.
Kluglein, Samantha
Quinn, Jessica
Sutter, Roland W.
Wang, Xiaochuan
Sanal, Ozden
Latysheva, Tatiana
Ikinciogullari, Aydan
Bernatowska, Ewa
Tuzankina, Irina A.
Costa-Carvalho, Beatriz T. [UNIFESP]
Luis Franco, Jose
Somech, Raz
Karakoc-Aydiner, Elif
Singh, Surjit
Bezrodnik, Liliana
Espinosa-Rosales, Francisco J.
Shcherbina, Anna
Lau, Yu-Lung
Nonoyama, Shigeaki
Modell, Fred
Modell, Vicki
Barbouche, Mohamed-Ridha
McKinlay, Mark A.
Institución
Resumen
Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame.
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study
Autor desconocido (Elsevier, 2021)Background: High-resolution estimates of HIV burden across space and time provide an important tool for tracking and monitoring the progress of prevention and control efforts and assist with improving the precision and ... -
Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program
Autor desconocido (Public Library of Science, 2017)Objective: Xpert MTB/RIF is recommended by the World Health Organization (WHO) as the initial tuberculosis (TB) diagnostic test in individuals suspected of HIV-associated TB. We sought to evaluate field implementation of ... -
Advances in primary immunodeficiency diseases in Latin America: epidemiology, research, and perspectives
Errante, Paolo Ruggero; Luis Franco, Jose; Javier Espinosa-Rosales, Francisco; Sorensen, Ricardo; Condino-Neto, Antonio (BLACKWELL SCIENCE PUBLOXFORD, 2012)Primary immunodeficiencies (PIDs) are genetic disorders of the immune system comprising many different phenotypes. Although previously considered rare, recent advances in their clinical, epidemiological, and molecular ...